LEVITRA® (vardenafil HCl), is effective at first dose with continued success in treating erectile dysfunction (ED) in men with associated medical conditions that affect the cardiovascular system.
These conditions included high blood pressure, diabetes and/or dyslipidemia, which includes high cholesterol and other lipid abnormalities.
These clinical data came from a randomized, placebo-controlled study that involved 600 patients with diagnosed ED who received a single open-label challenge dose of LEVITRA® 10 mg.
Belonging to a class of medications called oral phosphodiesterase type 5 (PDE5) inhibitors (the most commonly prescribed treatments for men with ED), LEVITRA® is an oral prescription medication approved by the USFDA for the treatment of erectile dysfunction (ED) in men.
Find more details from the press release.
Comment Preview